Heterocyclic compound, and intermediate and use thereof

By providing a heterocyclic compound with high inhibitory activity on ULK kinase, the problem of insufficient development of ULK inhibitors in the prior art in the treatment of cancer is solved, and effective inhibition of ULK kinase and potential therapeutic effect are improved.

WO2025045203A1PCT designated stage expired Publication Date: 2025-03-06ANHEART THERAPEUTICS (HANGZHOU) CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/115876
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-01
Filing Date
2024-08-30
Publication Date
2025-03-06

Smart Images

  • Figure CN2024115876_06032025_PF_FP_ABST
    Figure CN2024115876_06032025_PF_FP_ABST
Patent Text Reader

Abstract

A heterocyclic compound as represented by formula (I), or a racemate, enantiomer, tautomer, pharmaceutically acceptable salt or solvate thereof. Further disclosed is a pharmaceutical composition containing the heterocyclic compound, and an intermediate and the use of the heterocyclic compound. The heterocyclic compound has an ULK kinase inhibitory activity and can be used for treating diseases related to ULK kinase activity.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Amine-substituted aryl or heteroaryl compounds as EHMT1 and EHMT2 inhibitors

    CN109153650A

  • Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof

    CN114072397A

  • Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

    CN114127057A

  • Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation

    WO2009071535A1

  • Oxindolopyrimidine as IGF1r receptor inhibitors

    WO2012085126A1